 Douglas Seals
Concepts (763)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aging | 199 | 2025 | 1860 | 21.230 |
Why?
| | Endothelium, Vascular | 86 | 2025 | 934 | 15.420 |
Why?
| | Vascular Stiffness | 45 | 2025 | 443 | 9.830 |
Why?
| | Oxidative Stress | 65 | 2025 | 1327 | 8.360 |
Why?
| | Exercise | 102 | 2025 | 2082 | 8.150 |
Why?
| | Vasodilation | 62 | 2025 | 511 | 7.940 |
Why?
| | Arteries | 33 | 2024 | 263 | 6.530 |
Why?
| | Brachial Artery | 40 | 2025 | 203 | 6.340 |
Why?
| | Sympathetic Nervous System | 68 | 2025 | 175 | 6.260 |
Why?
| | Blood Pressure | 105 | 2025 | 1737 | 6.150 |
Why?
| | Writing | 8 | 2024 | 100 | 4.620 |
Why?
| | Biomedical Research | 11 | 2024 | 699 | 4.390 |
Why?
| | Carotid Arteries | 28 | 2024 | 195 | 4.270 |
Why?
| | Aorta | 19 | 2025 | 415 | 3.940 |
Why?
| | Vascular Diseases | 15 | 2023 | 242 | 3.700 |
Why?
| | Antioxidants | 24 | 2023 | 593 | 3.350 |
Why?
| | Nitric Oxide | 33 | 2023 | 895 | 3.310 |
Why?
| | Regional Blood Flow | 36 | 2020 | 501 | 3.260 |
Why?
| | Cardiovascular Diseases | 29 | 2025 | 2057 | 3.200 |
Why?
| | Physiology | 5 | 2024 | 14 | 3.060 |
Why?
| | Physical Endurance | 48 | 2016 | 273 | 3.040 |
Why?
| | Heart Rate | 84 | 2023 | 799 | 3.000 |
Why?
| | Sodium Nitrite | 8 | 2021 | 39 | 2.980 |
Why?
| | Publishing | 5 | 2023 | 146 | 2.950 |
Why?
| | Endothelial Cells | 21 | 2025 | 794 | 2.760 |
Why?
| | Postmenopause | 27 | 2025 | 376 | 2.750 |
Why?
| | Resistance Training | 5 | 2023 | 166 | 2.680 |
Why?
| | Aged | 179 | 2025 | 24237 | 2.640 |
Why?
| | Hypertension | 24 | 2025 | 1253 | 2.590 |
Why?
| | Dietary Supplements | 20 | 2025 | 562 | 2.420 |
Why?
| | Mitochondria | 10 | 2025 | 960 | 2.390 |
Why?
| | Caloric Restriction | 10 | 2021 | 124 | 2.350 |
Why?
| | Blood Vessels | 6 | 2020 | 181 | 2.350 |
Why?
| | Middle Aged | 200 | 2025 | 33867 | 2.300 |
Why?
| | Pulse Wave Analysis | 23 | 2025 | 233 | 2.260 |
Why?
| | Physical Exertion | 34 | 2014 | 209 | 2.230 |
Why?
| | Diet, Sodium-Restricted | 8 | 2020 | 38 | 2.180 |
Why?
| | Male | 261 | 2025 | 68330 | 2.070 |
Why?
| | Inflammation | 24 | 2024 | 2858 | 2.060 |
Why?
| | Nitric Oxide Synthase Type III | 13 | 2020 | 203 | 2.040 |
Why?
| | Humans | 349 | 2025 | 139073 | 2.040 |
Why?
| | Exercise Tolerance | 9 | 2025 | 278 | 2.040 |
Why?
| | Muscles | 32 | 2023 | 332 | 1.990 |
Why?
| | Ascorbic Acid | 17 | 2025 | 179 | 1.990 |
Why?
| | Physical Fitness | 20 | 2013 | 207 | 1.980 |
Why?
| | Baroreflex | 16 | 2016 | 57 | 1.950 |
Why?
| | Physical Conditioning, Animal | 10 | 2021 | 254 | 1.900 |
Why?
| | Oxygen Consumption | 47 | 2023 | 710 | 1.880 |
Why?
| | Cardiovascular Physiological Phenomena | 13 | 2019 | 44 | 1.880 |
Why?
| | NF-kappa B | 9 | 2015 | 680 | 1.860 |
Why?
| | Methylamines | 5 | 2022 | 34 | 1.850 |
Why?
| | Peer Review | 4 | 2023 | 50 | 1.820 |
Why?
| | Superoxides | 16 | 2022 | 217 | 1.820 |
Why?
| | Vasodilator Agents | 12 | 2024 | 329 | 1.780 |
Why?
| | Acetylcholine | 12 | 2023 | 205 | 1.680 |
Why?
| | Cellular Senescence | 8 | 2025 | 191 | 1.630 |
Why?
| | Norepinephrine | 29 | 2011 | 192 | 1.580 |
Why?
| | Adult | 203 | 2025 | 38394 | 1.550 |
Why?
| | Animals | 85 | 2025 | 37352 | 1.550 |
Why?
| | Mice | 54 | 2025 | 17867 | 1.550 |
Why?
| | Diet, Western | 3 | 2022 | 81 | 1.530 |
Why?
| | Heart | 16 | 2018 | 613 | 1.510 |
Why?
| | Female | 180 | 2025 | 74078 | 1.490 |
Why?
| | Adipose Tissue | 19 | 2018 | 643 | 1.440 |
Why?
| | Healthy Aging | 4 | 2024 | 36 | 1.440 |
Why?
| | Vascular Resistance | 20 | 2012 | 367 | 1.400 |
Why?
| | Motor Activity | 8 | 2024 | 715 | 1.350 |
Why?
| | Mice, Inbred C57BL | 28 | 2025 | 5813 | 1.340 |
Why?
| | Respiratory Muscles | 5 | 2023 | 34 | 1.330 |
Why?
| | Salicylates | 5 | 2015 | 29 | 1.330 |
Why?
| | Forearm | 18 | 2023 | 139 | 1.310 |
Why?
| | NADPH Oxidases | 13 | 2020 | 140 | 1.280 |
Why?
| | Autonomic Nervous System | 11 | 2008 | 78 | 1.230 |
Why?
| | Research Personnel | 4 | 2023 | 184 | 1.210 |
Why?
| | Age Factors | 29 | 2025 | 3276 | 1.190 |
Why?
| | Muscle, Skeletal | 23 | 2025 | 1740 | 1.190 |
Why?
| | Reactive Oxygen Species | 14 | 2025 | 630 | 1.180 |
Why?
| | Double-Blind Method | 17 | 2025 | 1947 | 1.180 |
Why?
| | Estrogens | 8 | 2023 | 369 | 1.160 |
Why?
| | Tyrosine | 14 | 2020 | 226 | 1.130 |
Why?
| | Healthy Lifestyle | 2 | 2018 | 34 | 1.120 |
Why?
| | Vasoconstriction | 7 | 2017 | 219 | 1.110 |
Why?
| | Aorta, Thoracic | 4 | 2014 | 275 | 1.070 |
Why?
| | Femoral Artery | 11 | 2013 | 183 | 1.060 |
Why?
| | NAD | 5 | 2023 | 79 | 1.040 |
Why?
| | Geriatrics | 4 | 2015 | 98 | 1.020 |
Why?
| | Smoking Water Pipes | 2 | 2023 | 9 | 1.020 |
Why?
| | Water Pipe Smoking | 2 | 2023 | 9 | 1.020 |
Why?
| | Estrogen Replacement Therapy | 12 | 2013 | 148 | 1.010 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 4 | 2015 | 358 | 0.990 |
Why?
| | Inflammation Mediators | 6 | 2025 | 513 | 0.990 |
Why?
| | Receptors, Adrenergic, beta | 6 | 2008 | 69 | 0.970 |
Why?
| | Metabolomics | 4 | 2021 | 692 | 0.930 |
Why?
| | Longevity | 4 | 2015 | 174 | 0.920 |
Why?
| | Cyclic N-Oxides | 8 | 2020 | 31 | 0.900 |
Why?
| | Interleukin-1 | 5 | 2022 | 966 | 0.890 |
Why?
| | Bottle-Nosed Dolphin | 1 | 2024 | 4 | 0.890 |
Why?
| | Curcumin | 2 | 2017 | 29 | 0.890 |
Why?
| | Elasticity | 11 | 2017 | 194 | 0.890 |
Why?
| | Drinking Water | 2 | 2022 | 84 | 0.870 |
Why?
| | Cross-Over Studies | 10 | 2023 | 553 | 0.870 |
Why?
| | Work-Life Balance | 1 | 2024 | 22 | 0.860 |
Why?
| | Habits | 7 | 2017 | 51 | 0.860 |
Why?
| | Doxorubicin | 3 | 2025 | 352 | 0.850 |
Why?
| | Niacinamide | 4 | 2025 | 82 | 0.840 |
Why?
| | Trehalose | 4 | 2017 | 32 | 0.830 |
Why?
| | Career Choice | 2 | 2024 | 232 | 0.830 |
Why?
| | Gastrointestinal Microbiome | 3 | 2020 | 700 | 0.820 |
Why?
| | Body Composition | 30 | 2012 | 696 | 0.820 |
Why?
| | Physical Education and Training | 15 | 2024 | 76 | 0.810 |
Why?
| | Body Temperature Regulation | 7 | 2007 | 100 | 0.810 |
Why?
| | Compliance | 15 | 2017 | 50 | 0.810 |
Why?
| | Fenofibrate | 2 | 2013 | 27 | 0.790 |
Why?
| | Human Umbilical Vein Endothelial Cells | 3 | 2021 | 107 | 0.790 |
Why?
| | Elastin | 6 | 2023 | 79 | 0.780 |
Why?
| | Goals | 1 | 2024 | 174 | 0.780 |
Why?
| | Vaping | 1 | 2023 | 61 | 0.770 |
Why?
| | Young Adult | 29 | 2025 | 13344 | 0.770 |
Why?
| | Transcriptome | 3 | 2023 | 971 | 0.770 |
Why?
| | Cardiorespiratory Fitness | 2 | 2021 | 57 | 0.770 |
Why?
| | Lyases | 1 | 2022 | 14 | 0.760 |
Why?
| | Nicotinamide Mononucleotide | 3 | 2023 | 9 | 0.760 |
Why?
| | Sodium, Dietary | 4 | 2013 | 39 | 0.760 |
Why?
| | Hypolipidemic Agents | 2 | 2013 | 90 | 0.760 |
Why?
| | Muscle Strength | 6 | 2023 | 321 | 0.750 |
Why?
| | Electronic Nicotine Delivery Systems | 1 | 2023 | 103 | 0.740 |
Why?
| | Rest | 13 | 2007 | 124 | 0.740 |
Why?
| | Obesity | 14 | 2023 | 3002 | 0.730 |
Why?
| | Speech | 1 | 2022 | 71 | 0.730 |
Why?
| | Research Design | 4 | 2022 | 1121 | 0.730 |
Why?
| | Hemodynamics | 17 | 2023 | 1095 | 0.730 |
Why?
| | Stress, Physiological | 12 | 2017 | 454 | 0.720 |
Why?
| | Aortitis | 2 | 2011 | 10 | 0.720 |
Why?
| | Vagus Nerve | 7 | 2005 | 88 | 0.720 |
Why?
| | Spirostans | 1 | 2021 | 4 | 0.710 |
Why?
| | Breathing Exercises | 1 | 2021 | 20 | 0.710 |
Why?
| | Leg | 14 | 2007 | 233 | 0.710 |
Why?
| | Inhalation | 1 | 2021 | 29 | 0.710 |
Why?
| | Spin Labels | 8 | 2020 | 52 | 0.700 |
Why?
| | Models, Animal | 6 | 2024 | 399 | 0.700 |
Why?
| | Running | 16 | 2017 | 230 | 0.690 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2021 | 1248 | 0.680 |
Why?
| | Isometric Contraction | 14 | 1996 | 178 | 0.670 |
Why?
| | Superoxide Dismutase | 9 | 2016 | 353 | 0.670 |
Why?
| | Reference Values | 26 | 2021 | 805 | 0.670 |
Why?
| | Autophagy | 3 | 2017 | 286 | 0.670 |
Why?
| | Comprehension | 1 | 2022 | 175 | 0.670 |
Why?
| | Biomarkers | 19 | 2025 | 4115 | 0.660 |
Why?
| | Life Style | 14 | 2017 | 484 | 0.660 |
Why?
| | Frailty | 2 | 2024 | 172 | 0.660 |
Why?
| | Cardiac Output | 15 | 2004 | 179 | 0.650 |
Why?
| | Cytokines | 10 | 2019 | 2084 | 0.650 |
Why?
| | Fasting | 2 | 2020 | 283 | 0.640 |
Why?
| | Nitroglycerin | 3 | 2020 | 14 | 0.640 |
Why?
| | Dementia | 1 | 2023 | 264 | 0.630 |
Why?
| | Spermidine | 2 | 2024 | 19 | 0.610 |
Why?
| | Nitrites | 3 | 2014 | 89 | 0.610 |
Why?
| | Renal Insufficiency, Chronic | 6 | 2025 | 621 | 0.610 |
Why?
| | Physical Conditioning, Human | 1 | 2019 | 42 | 0.610 |
Why?
| | Overweight | 3 | 2009 | 573 | 0.600 |
Why?
| | Cardiovascular System | 10 | 2020 | 138 | 0.600 |
Why?
| | Isoproterenol | 4 | 2007 | 101 | 0.600 |
Why?
| | Adrenergic beta-Agonists | 4 | 2007 | 97 | 0.590 |
Why?
| | Sex Characteristics | 13 | 2011 | 769 | 0.590 |
Why?
| | Adolescent | 46 | 2023 | 21561 | 0.590 |
Why?
| | Energy Metabolism | 9 | 2007 | 928 | 0.590 |
Why?
| | Lipids | 6 | 2018 | 676 | 0.590 |
Why?
| | Sirtuin 1 | 3 | 2016 | 30 | 0.590 |
Why?
| | Mentoring | 1 | 2021 | 153 | 0.580 |
Why?
| | Adaptation, Physiological | 8 | 2019 | 554 | 0.570 |
Why?
| | Amino Acids | 2 | 2019 | 500 | 0.570 |
Why?
| | Health Status | 3 | 2019 | 821 | 0.560 |
Why?
| | Lipoproteins, LDL | 10 | 2023 | 115 | 0.560 |
Why?
| | Body Constitution | 4 | 2005 | 54 | 0.550 |
Why?
| | Blood Volume | 8 | 1998 | 65 | 0.550 |
Why?
| | Sodium Chloride, Dietary | 3 | 2019 | 31 | 0.550 |
Why?
| | Glycation End Products, Advanced | 3 | 2013 | 83 | 0.550 |
Why?
| | Tunica Intima | 7 | 2006 | 76 | 0.540 |
Why?
| | Muscle, Smooth, Vascular | 6 | 2017 | 449 | 0.530 |
Why?
| | Nitroprusside | 5 | 2011 | 71 | 0.530 |
Why?
| | Diet | 6 | 2024 | 1287 | 0.520 |
Why?
| | Epinephrine | 14 | 2007 | 146 | 0.520 |
Why?
| | Extracellular Matrix | 1 | 2021 | 537 | 0.510 |
Why?
| | Serine | 2 | 2015 | 142 | 0.510 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2022 | 2144 | 0.510 |
Why?
| | Transcription Factor RelA | 4 | 2011 | 85 | 0.510 |
Why?
| | Basal Metabolism | 4 | 2004 | 62 | 0.500 |
Why?
| | Diet Therapy | 1 | 2016 | 37 | 0.500 |
Why?
| | Glucose | 4 | 2019 | 1032 | 0.500 |
Why?
| | Muscle Contraction | 13 | 2003 | 435 | 0.500 |
Why?
| | Cognition | 3 | 2025 | 1179 | 0.500 |
Why?
| | Primary Prevention | 1 | 2018 | 198 | 0.490 |
Why?
| | Time Factors | 21 | 2021 | 6885 | 0.490 |
Why?
| | Exercise Therapy | 8 | 2025 | 440 | 0.480 |
Why?
| | Estradiol | 3 | 2021 | 525 | 0.480 |
Why?
| | Premenopause | 9 | 2025 | 132 | 0.470 |
Why?
| | Blood Glucose | 10 | 2017 | 2191 | 0.460 |
Why?
| | Cross-Sectional Studies | 22 | 2020 | 5537 | 0.450 |
Why?
| | Body Mass Index | 18 | 2015 | 2388 | 0.450 |
Why?
| | Heterocyclic Compounds, 4 or More Rings | 1 | 2014 | 20 | 0.440 |
Why?
| | Hand Strength | 4 | 2025 | 133 | 0.440 |
Why?
| | Reflex | 6 | 2001 | 70 | 0.440 |
Why?
| | Collagen | 3 | 2021 | 458 | 0.440 |
Why?
| | Flavonols | 2 | 2025 | 18 | 0.440 |
Why?
| | Risk Factors | 19 | 2021 | 10426 | 0.440 |
Why?
| | AMP-Activated Protein Kinases | 3 | 2017 | 201 | 0.430 |
Why?
| | Endothelium | 1 | 2014 | 126 | 0.430 |
Why?
| | Ubiquinone | 1 | 2014 | 31 | 0.430 |
Why?
| | Geriatric Assessment | 2 | 2015 | 221 | 0.430 |
Why?
| | Nitrates | 4 | 2022 | 95 | 0.420 |
Why?
| | Niacin | 1 | 2013 | 17 | 0.420 |
Why?
| | Proteome | 1 | 2018 | 472 | 0.420 |
Why?
| | Bufanolides | 1 | 2013 | 4 | 0.420 |
Why?
| | Atherosclerosis | 1 | 2018 | 400 | 0.410 |
Why?
| | Hindlimb | 1 | 2014 | 133 | 0.410 |
Why?
| | Vitamin B Complex | 1 | 2013 | 42 | 0.410 |
Why?
| | Organophosphorus Compounds | 1 | 2014 | 78 | 0.400 |
Why?
| | Locomotion | 1 | 2014 | 105 | 0.400 |
Why?
| | Eating | 2 | 2007 | 395 | 0.400 |
Why?
| | Aortic Diseases | 1 | 2014 | 119 | 0.390 |
Why?
| | Risk Reduction Behavior | 1 | 2014 | 216 | 0.390 |
Why?
| | Exercise Test | 12 | 2021 | 622 | 0.390 |
Why?
| | Arm | 7 | 2008 | 108 | 0.390 |
Why?
| | Nitric Oxide Donors | 1 | 2012 | 21 | 0.380 |
Why?
| | Ganglionic Blockers | 7 | 2008 | 9 | 0.380 |
Why?
| | Repetitive Sequences, Nucleic Acid | 2 | 2024 | 114 | 0.380 |
Why?
| | Carotid Artery Diseases | 2 | 2010 | 61 | 0.380 |
Why?
| | Obesity, Abdominal | 1 | 2012 | 48 | 0.370 |
Why?
| | Allopurinol | 2 | 2016 | 62 | 0.370 |
Why?
| | Pressoreceptors | 6 | 2001 | 19 | 0.370 |
Why?
| | Dose-Response Relationship, Drug | 8 | 2015 | 2051 | 0.370 |
Why?
| | I-kappa B Proteins | 2 | 2009 | 76 | 0.360 |
Why?
| | Postural Balance | 1 | 2014 | 218 | 0.350 |
Why?
| | Adrenal Glands | 3 | 2000 | 75 | 0.350 |
Why?
| | Arteritis | 1 | 2011 | 27 | 0.350 |
Why?
| | Neurodegenerative Diseases | 2 | 2023 | 138 | 0.350 |
Why?
| | C-Reactive Protein | 3 | 2022 | 411 | 0.340 |
Why?
| | Ultrasonography | 11 | 2017 | 769 | 0.340 |
Why?
| | Oxidants | 1 | 2011 | 112 | 0.340 |
Why?
| | Systole | 6 | 2020 | 175 | 0.340 |
Why?
| | Uric Acid | 1 | 2012 | 165 | 0.340 |
Why?
| | Colorado | 6 | 2024 | 4532 | 0.340 |
Why?
| | Behavior, Animal | 1 | 2014 | 512 | 0.330 |
Why?
| | Pilot Projects | 5 | 2025 | 1763 | 0.330 |
Why?
| | Athletic Performance | 2 | 2012 | 80 | 0.330 |
Why?
| | Cholesterol, LDL | 5 | 2008 | 359 | 0.330 |
Why?
| | Analysis of Variance | 7 | 2011 | 1320 | 0.320 |
Why?
| | Forkhead Transcription Factors | 1 | 2011 | 201 | 0.320 |
Why?
| | Athletes | 2 | 2022 | 425 | 0.320 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2010 | 165 | 0.310 |
Why?
| | Antineoplastic Agents | 1 | 2021 | 2162 | 0.310 |
Why?
| | Metabolome | 3 | 2018 | 354 | 0.310 |
Why?
| | Peroxidase | 1 | 2010 | 183 | 0.310 |
Why?
| | Receptors, Adrenergic, beta-2 | 2 | 2007 | 33 | 0.310 |
Why?
| | Hot Temperature | 5 | 1993 | 395 | 0.300 |
Why?
| | Interleukins | 2 | 2022 | 251 | 0.300 |
Why?
| | Extremities | 2 | 2001 | 137 | 0.300 |
Why?
| | Blood Circulation | 4 | 2021 | 44 | 0.300 |
Why?
| | Biological Availability | 4 | 2021 | 138 | 0.300 |
Why?
| | Anti-Bacterial Agents | 1 | 2019 | 1812 | 0.290 |
Why?
| | Vitamin D Deficiency | 1 | 2010 | 188 | 0.290 |
Why?
| | Administration, Oral | 5 | 2015 | 790 | 0.290 |
Why?
| | Vitamin D | 2 | 2017 | 399 | 0.290 |
Why?
| | Healthy Volunteers | 3 | 2018 | 208 | 0.290 |
Why?
| | Ventricular Function, Left | 3 | 2003 | 503 | 0.290 |
Why?
| | Cells, Cultured | 5 | 2025 | 4182 | 0.290 |
Why?
| | Endothelin-1 | 2 | 2009 | 177 | 0.290 |
Why?
| | Interleukin-6 | 4 | 2024 | 786 | 0.290 |
Why?
| | NG-Nitroarginine Methyl Ester | 4 | 2013 | 49 | 0.290 |
Why?
| | Energy Intake | 6 | 2020 | 506 | 0.290 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 1 | 2008 | 48 | 0.290 |
Why?
| | Cerebrovascular Circulation | 3 | 2025 | 267 | 0.290 |
Why?
| | Upper Extremity | 1 | 2009 | 105 | 0.290 |
Why?
| | Signal Transduction | 6 | 2014 | 5094 | 0.290 |
Why?
| | Kidney | 7 | 2025 | 1480 | 0.280 |
Why?
| | Leukocytes, Mononuclear | 1 | 2011 | 571 | 0.280 |
Why?
| | Collagen Type I | 3 | 2014 | 139 | 0.280 |
Why?
| | Peroneal Nerve | 5 | 2000 | 18 | 0.280 |
Why?
| | Cognitive Dysfunction | 2 | 2025 | 391 | 0.280 |
Why?
| | Oxygen | 11 | 2022 | 976 | 0.280 |
Why?
| | Posture | 6 | 2001 | 192 | 0.280 |
Why?
| | Hypercapnia | 2 | 2025 | 54 | 0.270 |
Why?
| | Sports | 5 | 2003 | 235 | 0.270 |
Why?
| | Abdomen | 5 | 2004 | 136 | 0.270 |
Why?
| | Phosphorylation | 6 | 2013 | 1770 | 0.270 |
Why?
| | Infusions, Intravenous | 5 | 2014 | 415 | 0.270 |
Why?
| | Adiposity | 1 | 2012 | 522 | 0.270 |
Why?
| | Treatment Outcome | 7 | 2025 | 10965 | 0.270 |
Why?
| | Regression Analysis | 10 | 2011 | 1015 | 0.270 |
Why?
| | Human Experimentation | 1 | 2007 | 14 | 0.270 |
Why?
| | Acetophenones | 3 | 2019 | 14 | 0.260 |
Why?
| | Trimethaphan | 5 | 2005 | 6 | 0.260 |
Why?
| | Enzyme Inhibitors | 4 | 2016 | 850 | 0.260 |
Why?
| | Electrocardiography | 9 | 2005 | 614 | 0.260 |
Why?
| | Tunica Media | 3 | 2001 | 35 | 0.260 |
Why?
| | Phenylephrine | 5 | 2005 | 75 | 0.260 |
Why?
| | Swimming | 5 | 2002 | 50 | 0.260 |
Why?
| | Congresses as Topic | 2 | 2018 | 230 | 0.250 |
Why?
| | Hypoxia | 6 | 1999 | 1146 | 0.250 |
Why?
| | Nitric Oxide Synthase | 3 | 2014 | 241 | 0.250 |
Why?
| | Gene Expression Regulation | 3 | 2017 | 2602 | 0.250 |
Why?
| | Proteins | 3 | 2009 | 1014 | 0.250 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2008 | 551 | 0.240 |
Why?
| | Fatty Acids | 2 | 2019 | 446 | 0.240 |
Why?
| | Microcirculation | 2 | 2019 | 150 | 0.240 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2007 | 277 | 0.240 |
Why?
| | Brain | 6 | 2023 | 2790 | 0.240 |
Why?
| | Recovery of Function | 4 | 2017 | 666 | 0.240 |
Why?
| | Thermogenesis | 1 | 2005 | 44 | 0.240 |
Why?
| | Carbon Dioxide | 3 | 2023 | 240 | 0.230 |
Why?
| | Sodium Bicarbonate | 1 | 2025 | 46 | 0.230 |
Why?
| | Receptors, Adrenergic, alpha | 2 | 2002 | 21 | 0.230 |
Why?
| | Cell Nucleus | 1 | 2008 | 611 | 0.230 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 2 | 2011 | 42 | 0.230 |
Why?
| | MicroRNAs | 1 | 2011 | 680 | 0.230 |
Why?
| | Arginine | 1 | 2006 | 261 | 0.230 |
Why?
| | Flavonoids | 1 | 2025 | 85 | 0.230 |
Why?
| | American Heart Association | 2 | 2020 | 284 | 0.230 |
Why?
| | Carotid Artery, Internal | 1 | 2025 | 44 | 0.220 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2025 | 125 | 0.220 |
Why?
| | Preventive Medicine | 2 | 2015 | 40 | 0.220 |
Why?
| | Acidosis | 1 | 2025 | 105 | 0.220 |
Why?
| | Veins | 5 | 2009 | 66 | 0.220 |
Why?
| | Apigenin | 1 | 2023 | 3 | 0.210 |
Why?
| | Aged, 80 and over | 13 | 2025 | 7699 | 0.210 |
Why?
| | Case-Control Studies | 4 | 2025 | 3585 | 0.210 |
Why?
| | Skin | 4 | 2019 | 754 | 0.210 |
Why?
| | Respiratory Therapy | 1 | 2023 | 25 | 0.210 |
Why?
| | Weight Loss | 2 | 2008 | 785 | 0.210 |
Why?
| | Lactates | 7 | 2007 | 85 | 0.200 |
Why?
| | History, 21st Century | 1 | 2024 | 215 | 0.200 |
Why?
| | Xanthine Oxidase | 3 | 2009 | 81 | 0.200 |
Why?
| | Blueberry Plants | 1 | 2023 | 7 | 0.200 |
Why?
| | Tissue Culture Techniques | 2 | 2014 | 82 | 0.200 |
Why?
| | Pyridinium Compounds | 2 | 2025 | 28 | 0.200 |
Why?
| | Hand | 8 | 1994 | 160 | 0.200 |
Why?
| | History, 20th Century | 1 | 2024 | 327 | 0.200 |
Why?
| | Blood Flow Velocity | 6 | 2019 | 418 | 0.200 |
Why?
| | Myocardium | 5 | 2010 | 922 | 0.190 |
Why?
| | Drug Evaluation, Preclinical | 2 | 2014 | 194 | 0.190 |
Why?
| | Cholesterol | 5 | 1997 | 401 | 0.190 |
Why?
| | Anthropometry | 3 | 2011 | 212 | 0.190 |
Why?
| | Fibrinolysis | 2 | 2008 | 147 | 0.190 |
Why?
| | Kidney Diseases | 2 | 2025 | 407 | 0.190 |
Why?
| | Apoptosis | 1 | 2011 | 2559 | 0.190 |
Why?
| | Acetylene | 2 | 2003 | 3 | 0.190 |
Why?
| | Authorship | 1 | 2023 | 54 | 0.190 |
Why?
| | Supine Position | 6 | 1999 | 37 | 0.190 |
Why?
| | Cold Temperature | 7 | 2001 | 185 | 0.190 |
Why?
| | Sugars | 1 | 2022 | 39 | 0.190 |
Why?
| | Adrenal Medulla | 1 | 2002 | 9 | 0.190 |
Why?
| | Respiration | 7 | 1998 | 207 | 0.190 |
Why?
| | Coronary Disease | 6 | 1998 | 374 | 0.180 |
Why?
| | Citrulline | 1 | 2022 | 45 | 0.180 |
Why?
| | Terminology as Topic | 1 | 2023 | 247 | 0.180 |
Why?
| | Universities | 1 | 2024 | 440 | 0.180 |
Why?
| | Body Weight | 10 | 2019 | 995 | 0.180 |
Why?
| | Cyclooxygenase 2 | 2 | 2014 | 176 | 0.180 |
Why?
| | Insulin | 11 | 2022 | 2407 | 0.170 |
Why?
| | Sirolimus | 3 | 2021 | 280 | 0.170 |
Why?
| | Fatty Liver | 1 | 2023 | 241 | 0.170 |
Why?
| | Progesterone | 1 | 2002 | 258 | 0.170 |
Why?
| | I-kappa B Kinase | 2 | 2011 | 54 | 0.170 |
Why?
| | Weight Gain | 1 | 2004 | 538 | 0.170 |
Why?
| | Nicotine | 1 | 2023 | 347 | 0.170 |
Why?
| | Free Radical Scavengers | 2 | 2013 | 87 | 0.170 |
Why?
| | Manuscripts as Topic | 1 | 2000 | 2 | 0.170 |
Why?
| | Extracellular Vesicles | 1 | 2022 | 148 | 0.170 |
Why?
| | Mexican Americans | 1 | 2001 | 114 | 0.170 |
Why?
| | DNA Transposable Elements | 1 | 2021 | 122 | 0.160 |
Why?
| | Knee | 1 | 2000 | 69 | 0.160 |
Why?
| | DNA Methylation | 2 | 2024 | 638 | 0.160 |
Why?
| | Lipocalin-2 | 1 | 2020 | 79 | 0.160 |
Why?
| | Lung | 4 | 1999 | 4094 | 0.160 |
Why?
| | Triglycerides | 4 | 2017 | 515 | 0.160 |
Why?
| | Myocardial Reperfusion Injury | 2 | 2011 | 148 | 0.160 |
Why?
| | Fibrinogen | 2 | 1998 | 173 | 0.160 |
Why?
| | RNA, Untranslated | 1 | 2021 | 124 | 0.160 |
Why?
| | Functional Food | 1 | 2019 | 3 | 0.160 |
Why?
| | Pulmonary Circulation | 1 | 2001 | 438 | 0.160 |
Why?
| | Waist-Hip Ratio | 2 | 2012 | 40 | 0.150 |
Why?
| | Menopause | 2 | 2006 | 326 | 0.150 |
Why?
| | Adrenergic alpha-Agonists | 3 | 2005 | 28 | 0.150 |
Why?
| | Drug Monitoring | 1 | 2021 | 211 | 0.150 |
Why?
| | Mentors | 1 | 2021 | 210 | 0.150 |
Why?
| | Adipose Tissue, White | 1 | 2019 | 43 | 0.150 |
Why?
| | Fluorescent Antibody Technique | 3 | 2009 | 384 | 0.150 |
Why?
| | Adipokines | 1 | 2019 | 47 | 0.150 |
Why?
| | Rats | 11 | 2015 | 5598 | 0.150 |
Why?
| | Transforming Growth Factor beta | 2 | 2012 | 487 | 0.150 |
Why?
| | NF-KappaB Inhibitor alpha | 2 | 2009 | 50 | 0.150 |
Why?
| | Stroke Volume | 7 | 1998 | 580 | 0.150 |
Why?
| | Glomerular Filtration Rate | 2 | 2025 | 746 | 0.150 |
Why?
| | Lower Body Negative Pressure | 4 | 1992 | 25 | 0.150 |
Why?
| | Social Class | 1 | 2001 | 279 | 0.150 |
Why?
| | Linear Models | 2 | 2012 | 856 | 0.140 |
Why?
| | Guidelines as Topic | 1 | 2020 | 272 | 0.140 |
Why?
| | Cohort Studies | 5 | 2013 | 5736 | 0.140 |
Why?
| | Metabolic Syndrome | 2 | 2019 | 348 | 0.140 |
Why?
| | Cardiology | 1 | 2020 | 277 | 0.140 |
Why?
| | Methionine | 1 | 2018 | 162 | 0.140 |
Why?
| | Leptin | 5 | 2019 | 242 | 0.140 |
Why?
| | Adipocytes | 1 | 2019 | 227 | 0.140 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 1997 | 142 | 0.130 |
Why?
| | Unfolded Protein Response | 2 | 2017 | 60 | 0.130 |
Why?
| | Calcitriol | 1 | 2017 | 59 | 0.130 |
Why?
| | Cholecalciferol | 1 | 2017 | 60 | 0.130 |
Why?
| | Neuromuscular Junction | 2 | 1995 | 63 | 0.130 |
Why?
| | Carotid Artery, Common | 1 | 2017 | 30 | 0.130 |
Why?
| | Disease Models, Animal | 4 | 2025 | 4339 | 0.130 |
Why?
| | Heart Conduction System | 4 | 2002 | 89 | 0.130 |
Why?
| | Stress, Psychological | 3 | 1995 | 1124 | 0.130 |
Why?
| | Hyperuricemia | 1 | 2016 | 45 | 0.130 |
Why?
| | Education, Graduate | 1 | 2016 | 34 | 0.130 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2017 | 118 | 0.120 |
Why?
| | Students, Health Occupations | 1 | 2016 | 33 | 0.120 |
Why?
| | Blood Coagulation | 1 | 1998 | 265 | 0.120 |
Why?
| | Insulin Resistance | 3 | 2018 | 1225 | 0.120 |
Why?
| | Age Distribution | 1 | 1997 | 398 | 0.120 |
Why?
| | Methemoglobin | 1 | 2015 | 21 | 0.120 |
Why?
| | Gene Regulatory Networks | 1 | 2018 | 311 | 0.120 |
Why?
| | Walking | 3 | 2011 | 535 | 0.120 |
Why?
| | Risk Assessment | 2 | 2018 | 3470 | 0.120 |
Why?
| | Hemostasis | 2 | 1998 | 87 | 0.120 |
Why?
| | Program Development | 1 | 2018 | 362 | 0.120 |
Why?
| | Myocardial Contraction | 3 | 1988 | 303 | 0.120 |
Why?
| | Anaerobic Threshold | 3 | 2008 | 28 | 0.120 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 1995 | 54 | 0.110 |
Why?
| | Middle Cerebral Artery | 2 | 2025 | 53 | 0.110 |
Why?
| | NADPH Oxidase 4 | 1 | 2014 | 8 | 0.110 |
Why?
| | Urinalysis | 1 | 2015 | 77 | 0.110 |
Why?
| | Sex Factors | 3 | 2025 | 2056 | 0.110 |
Why?
| | Lipid Metabolism | 1 | 2018 | 525 | 0.110 |
Why?
| | Src Homology 2 Domain-Containing, Transforming Protein 1 | 1 | 2014 | 12 | 0.110 |
Why?
| | Shc Signaling Adaptor Proteins | 1 | 2014 | 12 | 0.110 |
Why?
| | Skinfold Thickness | 4 | 1999 | 46 | 0.110 |
Why?
| | Rotenone | 1 | 2014 | 11 | 0.110 |
Why?
| | Rejuvenation | 1 | 2014 | 19 | 0.110 |
Why?
| | Mitochondrial Proteins | 1 | 2016 | 258 | 0.110 |
Why?
| | Neurons | 2 | 1995 | 1606 | 0.110 |
Why?
| | Nutritional Status | 1 | 2016 | 352 | 0.100 |
Why?
| | Mobility Limitation | 1 | 2014 | 60 | 0.100 |
Why?
| | Liver | 3 | 2017 | 1882 | 0.100 |
Why?
| | Plasma Volume | 3 | 2002 | 20 | 0.100 |
Why?
| | Cell Cycle | 1 | 2016 | 598 | 0.100 |
Why?
| | Cardiotonic Agents | 1 | 2014 | 95 | 0.100 |
Why?
| | Administration, Cutaneous | 1 | 2013 | 129 | 0.100 |
Why?
| | Program Evaluation | 1 | 2018 | 913 | 0.100 |
Why?
| | Plethysmography | 4 | 2007 | 108 | 0.100 |
Why?
| | Multivariate Analysis | 2 | 2012 | 1498 | 0.100 |
Why?
| | Epidemiology | 1 | 2013 | 33 | 0.100 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 1994 | 119 | 0.100 |
Why?
| | Diabetic Angiopathies | 1 | 2015 | 250 | 0.100 |
Why?
| | Statistics as Topic | 2 | 2011 | 299 | 0.100 |
Why?
| | Absorptiometry, Photon | 2 | 2012 | 263 | 0.100 |
Why?
| | Respiratory Mechanics | 1 | 1993 | 70 | 0.100 |
Why?
| | Administration, Sublingual | 1 | 2012 | 12 | 0.100 |
Why?
| | Body Temperature | 5 | 1991 | 223 | 0.100 |
Why?
| | Hypotension | 1 | 1993 | 120 | 0.100 |
Why?
| | Pyrogallol | 1 | 2012 | 3 | 0.100 |
Why?
| | Catecholamines | 5 | 1996 | 91 | 0.090 |
Why?
| | Mental Processes | 1 | 1992 | 35 | 0.090 |
Why?
| | Aminoimidazole Carboxamide | 1 | 2012 | 12 | 0.090 |
Why?
| | Prospective Studies | 6 | 2021 | 7660 | 0.090 |
Why?
| | Ribonucleotides | 1 | 2012 | 26 | 0.090 |
Why?
| | Pulmonary Gas Exchange | 4 | 2007 | 125 | 0.090 |
Why?
| | Waist Circumference | 1 | 2012 | 140 | 0.090 |
Why?
| | Naphthols | 1 | 2011 | 7 | 0.090 |
Why?
| | Hysterectomy | 1 | 2012 | 141 | 0.090 |
Why?
| | Receptors, Adrenergic, beta-3 | 1 | 2011 | 4 | 0.090 |
Why?
| | Nitroso Compounds | 1 | 2011 | 7 | 0.090 |
Why?
| | Myography | 1 | 2011 | 7 | 0.090 |
Why?
| | Metabolism | 2 | 2001 | 43 | 0.090 |
Why?
| | Chemokine CCL2 | 1 | 2011 | 116 | 0.090 |
Why?
| | Least-Squares Analysis | 1 | 2011 | 78 | 0.090 |
Why?
| | Forkhead Box Protein O3 | 1 | 2011 | 17 | 0.090 |
Why?
| | 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2010 | 17 | 0.090 |
Why?
| | Diastole | 3 | 2003 | 141 | 0.090 |
Why?
| | Retrospective Studies | 4 | 2022 | 15924 | 0.090 |
Why?
| | Glucose Tolerance Test | 3 | 2018 | 366 | 0.090 |
Why?
| | Connective Tissue | 1 | 2010 | 39 | 0.080 |
Why?
| | Endorphins | 1 | 1990 | 11 | 0.080 |
Why?
| | Mice, Inbred Strains | 1 | 2011 | 411 | 0.080 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2010 | 57 | 0.080 |
Why?
| | Receptors, Calcitriol | 1 | 2010 | 55 | 0.080 |
Why?
| | United States | 3 | 2020 | 15065 | 0.080 |
Why?
| | Caspases | 1 | 2011 | 244 | 0.080 |
Why?
| | Oxidation-Reduction | 1 | 2014 | 1079 | 0.080 |
Why?
| | Benzamides | 1 | 2011 | 213 | 0.080 |
Why?
| | Decompression | 1 | 1990 | 3 | 0.080 |
Why?
| | Phosphoproteins | 1 | 2012 | 340 | 0.080 |
Why?
| | Communication | 1 | 2016 | 932 | 0.080 |
Why?
| | Lipoproteins, HDL | 3 | 1984 | 77 | 0.080 |
Why?
| | Fibronectins | 1 | 2010 | 132 | 0.080 |
Why?
| | Prediabetic State | 1 | 2013 | 247 | 0.080 |
Why?
| | Follow-Up Studies | 2 | 2018 | 5167 | 0.080 |
Why?
| | Phenotype | 2 | 2024 | 3160 | 0.080 |
Why?
| | Curriculum | 1 | 2016 | 1010 | 0.080 |
Why?
| | Diet Records | 1 | 2009 | 83 | 0.080 |
Why?
| | Subclavian Artery | 1 | 1989 | 28 | 0.080 |
Why?
| | Cyclooxygenase 1 | 1 | 2009 | 28 | 0.080 |
Why?
| | Receptor, Endothelin A | 1 | 2009 | 63 | 0.080 |
Why?
| | Prognosis | 1 | 2018 | 4024 | 0.080 |
Why?
| | Leukocyte Count | 1 | 2010 | 327 | 0.080 |
Why?
| | Acclimatization | 1 | 1990 | 171 | 0.080 |
Why?
| | Probability | 1 | 2010 | 309 | 0.070 |
Why?
| | Carotid Sinus | 1 | 1988 | 2 | 0.070 |
Why?
| | Blood Pressure Determination | 1 | 2010 | 144 | 0.070 |
Why?
| | Arrhythmia, Sinus | 1 | 1988 | 3 | 0.070 |
Why?
| | Sulfaphenazole | 1 | 2008 | 3 | 0.070 |
Why?
| | Homeostasis | 3 | 2021 | 617 | 0.070 |
Why?
| | Cytochrome P-450 CYP2C9 | 1 | 2008 | 20 | 0.070 |
Why?
| | omega-N-Methylarginine | 1 | 2008 | 31 | 0.070 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2010 | 259 | 0.070 |
Why?
| | Rats, Sprague-Dawley | 2 | 2010 | 2497 | 0.070 |
Why?
| | Tetralogy of Fallot | 1 | 1989 | 71 | 0.070 |
Why?
| | Biomechanical Phenomena | 1 | 2012 | 820 | 0.070 |
Why?
| | Aortic Coarctation | 1 | 1989 | 79 | 0.070 |
Why?
| | Propranolol | 4 | 2001 | 45 | 0.070 |
Why?
| | Diet, High-Fat | 2 | 2021 | 248 | 0.070 |
Why?
| | Leukocytes | 1 | 2010 | 309 | 0.070 |
Why?
| | Calorimetry, Indirect | 2 | 2005 | 85 | 0.070 |
Why?
| | Estrogen Receptor alpha | 1 | 2009 | 146 | 0.070 |
Why?
| | Microscopy, Fluorescence | 1 | 2009 | 413 | 0.070 |
Why?
| | Interferon-gamma | 1 | 2011 | 789 | 0.070 |
Why?
| | Vasoconstrictor Agents | 2 | 2007 | 133 | 0.070 |
Why?
| | Hyperemia | 1 | 1988 | 50 | 0.070 |
Why?
| | Hyperoxia | 2 | 1999 | 91 | 0.070 |
Why?
| | Databases, Factual | 1 | 2013 | 1404 | 0.070 |
Why?
| | Catalase | 1 | 2007 | 134 | 0.070 |
Why?
| | Electrophysiology | 3 | 1993 | 217 | 0.070 |
Why?
| | Kinetics | 3 | 1997 | 1656 | 0.060 |
Why?
| | Telomere | 1 | 2010 | 277 | 0.060 |
Why?
| | Amidohydrolases | 1 | 2006 | 31 | 0.060 |
Why?
| | Gene Expression | 1 | 2011 | 1494 | 0.060 |
Why?
| | Severity of Illness Index | 2 | 2016 | 2865 | 0.060 |
Why?
| | Data Interpretation, Statistical | 1 | 2008 | 364 | 0.060 |
Why?
| | Hormones | 2 | 2002 | 142 | 0.060 |
Why?
| | Adrenergic beta-Antagonists | 3 | 2001 | 229 | 0.060 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2007 | 140 | 0.060 |
Why?
| | Body Fat Distribution | 1 | 2005 | 50 | 0.060 |
Why?
| | Hematocrit | 2 | 1997 | 104 | 0.060 |
Why?
| | Heart Ventricles | 3 | 2003 | 741 | 0.060 |
Why?
| | Codon | 1 | 2005 | 92 | 0.060 |
Why?
| | Ultrasonography, Doppler, Transcranial | 1 | 2025 | 42 | 0.060 |
Why?
| | Fibroblasts | 1 | 2010 | 1003 | 0.060 |
Why?
| | Dihydroxyphenylalanine | 2 | 1995 | 9 | 0.060 |
Why?
| | Methoxyhydroxyphenylglycol | 2 | 1995 | 13 | 0.060 |
Why?
| | Aniline Compounds | 1 | 2025 | 104 | 0.060 |
Why?
| | Erythrocyte Volume | 2 | 1994 | 6 | 0.060 |
Why?
| | Vital Capacity | 2 | 2000 | 304 | 0.060 |
Why?
| | Vasopressins | 1 | 2005 | 59 | 0.060 |
Why?
| | Thigh | 2 | 2003 | 48 | 0.060 |
Why?
| | Calorimetry | 1 | 2004 | 71 | 0.050 |
Why?
| | Recombinant Proteins | 2 | 2018 | 1361 | 0.050 |
Why?
| | Osmolar Concentration | 3 | 2001 | 168 | 0.050 |
Why?
| | Up-Regulation | 1 | 2007 | 854 | 0.050 |
Why?
| | Postprandial Period | 1 | 2004 | 109 | 0.050 |
Why?
| | Stroke | 2 | 2011 | 1138 | 0.050 |
Why?
| | Cell Proliferation | 1 | 2011 | 2486 | 0.050 |
Why?
| | Stem Cells | 1 | 2008 | 599 | 0.050 |
Why?
| | Elastic Modulus | 1 | 2024 | 123 | 0.050 |
Why?
| | Mice, Transgenic | 2 | 2019 | 2177 | 0.050 |
Why?
| | Macrophages | 1 | 2011 | 1545 | 0.050 |
Why?
| | RNA, Messenger | 1 | 2011 | 2822 | 0.050 |
Why?
| | Powders | 1 | 2023 | 41 | 0.050 |
Why?
| | Butanols | 1 | 2022 | 6 | 0.050 |
Why?
| | T-Lymphocytes | 1 | 2011 | 1983 | 0.050 |
Why?
| | Biology | 1 | 2023 | 90 | 0.050 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2023 | 133 | 0.050 |
Why?
| | Femur | 2 | 2001 | 260 | 0.050 |
Why?
| | Evans Blue | 1 | 2002 | 8 | 0.050 |
Why?
| | Rats, Inbred Strains | 3 | 1991 | 346 | 0.050 |
Why?
| | Phenols | 1 | 2023 | 104 | 0.050 |
Why?
| | Electromyography | 3 | 1989 | 399 | 0.050 |
Why?
| | Ganglia, Autonomic | 1 | 2001 | 5 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 1 | 2012 | 2706 | 0.050 |
Why?
| | Phentolamine | 1 | 2001 | 18 | 0.050 |
Why?
| | Mesentery | 1 | 2002 | 46 | 0.050 |
Why?
| | Adrenergic alpha-Antagonists | 1 | 2001 | 34 | 0.050 |
Why?
| | Ischemia | 5 | 1994 | 416 | 0.050 |
Why?
| | Infusions, Intra-Arterial | 1 | 2001 | 61 | 0.050 |
Why?
| | Respiratory Function Tests | 2 | 1994 | 559 | 0.050 |
Why?
| | Men | 1 | 2001 | 22 | 0.040 |
Why?
| | Genotype | 1 | 2007 | 1873 | 0.040 |
Why?
| | Lactic Acid | 4 | 1995 | 306 | 0.040 |
Why?
| | Sulfonamides | 1 | 2025 | 511 | 0.040 |
Why?
| | Acarbose | 1 | 2021 | 3 | 0.040 |
Why?
| | Drugs, Chinese Herbal | 1 | 2021 | 21 | 0.040 |
Why?
| | Tidal Volume | 2 | 1993 | 102 | 0.040 |
Why?
| | Blood Viscosity | 1 | 2001 | 18 | 0.040 |
Why?
| | Models, Biological | 2 | 2004 | 1818 | 0.040 |
Why?
| | Neurons, Afferent | 2 | 1993 | 98 | 0.040 |
Why?
| | Clinical Trials as Topic | 2 | 2014 | 1036 | 0.040 |
Why?
| | Thoracic Arteries | 1 | 2000 | 4 | 0.040 |
Why?
| | Catheterization | 1 | 2001 | 181 | 0.040 |
Why?
| | Pressure | 1 | 2001 | 227 | 0.040 |
Why?
| | Mouth | 1 | 2021 | 87 | 0.040 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2020 | 42 | 0.040 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2015 | 2515 | 0.040 |
Why?
| | Hypertrophy | 1 | 2001 | 133 | 0.040 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2003 | 362 | 0.040 |
Why?
| | Organ Size | 2 | 2016 | 474 | 0.040 |
Why?
| | Thinness | 1 | 2000 | 95 | 0.040 |
Why?
| | Mexico | 1 | 2001 | 233 | 0.040 |
Why?
| | Stress, Mechanical | 2 | 2001 | 487 | 0.040 |
Why?
| | Rats, Inbred F344 | 2 | 1990 | 267 | 0.040 |
Why?
| | Corticotropin-Releasing Hormone | 2 | 1991 | 75 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2005 | 2045 | 0.040 |
Why?
| | NADP | 1 | 2019 | 54 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2024 | 648 | 0.040 |
Why?
| | Head-Down Tilt | 1 | 1999 | 6 | 0.040 |
Why?
| | Myocardial Infarction | 2 | 2005 | 1069 | 0.040 |
Why?
| | Receptors, Interleukin-1 Type I | 1 | 2018 | 24 | 0.040 |
Why?
| | Antihypertensive Agents | 1 | 2022 | 501 | 0.040 |
Why?
| | Hyperinsulinism | 1 | 2019 | 124 | 0.040 |
Why?
| | Immunity, Innate | 1 | 2024 | 828 | 0.040 |
Why?
| | Prevalence | 2 | 2005 | 2746 | 0.030 |
Why?
| | Oncogene Protein p21(ras) | 1 | 2017 | 16 | 0.030 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 1998 | 86 | 0.030 |
Why?
| | Biological Transport | 1 | 2019 | 403 | 0.030 |
Why?
| | Acute Disease | 1 | 2000 | 1011 | 0.030 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 1998 | 91 | 0.030 |
Why?
| | Mathematics | 2 | 1996 | 101 | 0.030 |
Why?
| | Automation | 1 | 1997 | 97 | 0.030 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 1998 | 145 | 0.030 |
Why?
| | Rotarod Performance Test | 1 | 2017 | 16 | 0.030 |
Why?
| | Echocardiography | 2 | 2005 | 639 | 0.030 |
Why?
| | Splanchnic Circulation | 2 | 1999 | 12 | 0.030 |
Why?
| | Cell Respiration | 1 | 2017 | 103 | 0.030 |
Why?
| | Adenylate Kinase | 1 | 2016 | 27 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2001 | 1310 | 0.030 |
Why?
| | Weight Lifting | 3 | 1988 | 32 | 0.030 |
Why?
| | Muscle Development | 1 | 1997 | 115 | 0.030 |
Why?
| | Myoblasts | 1 | 2017 | 82 | 0.030 |
Why?
| | Body Height | 1 | 1997 | 196 | 0.030 |
Why?
| | Tissue Plasminogen Activator | 1 | 1998 | 231 | 0.030 |
Why?
| | Receptors, Interleukin-1 | 1 | 2017 | 215 | 0.030 |
Why?
| | Oxidative Phosphorylation | 1 | 2017 | 194 | 0.030 |
Why?
| | Pain | 2 | 1992 | 780 | 0.030 |
Why?
| | Longitudinal Studies | 2 | 2019 | 2846 | 0.030 |
Why?
| | Cholesterol, HDL | 3 | 1984 | 196 | 0.030 |
Why?
| | Resilience, Psychological | 1 | 2017 | 127 | 0.030 |
Why?
| | Indicator Dilution Techniques | 1 | 1995 | 12 | 0.030 |
Why?
| | Haplorhini | 1 | 2015 | 53 | 0.030 |
Why?
| | Menstruation | 1 | 1995 | 43 | 0.030 |
Why?
| | Receptors, Leptin | 1 | 2015 | 25 | 0.030 |
Why?
| | Protein Kinases | 1 | 2017 | 308 | 0.030 |
Why?
| | Autonomic Fibers, Postganglionic | 1 | 1994 | 1 | 0.030 |
Why?
| | Spectrophotometry | 1 | 1994 | 60 | 0.030 |
Why?
| | Median Nerve | 1 | 1994 | 27 | 0.030 |
Why?
| | Neurotransmitter Agents | 1 | 1995 | 81 | 0.030 |
Why?
| | Homozygote | 1 | 2015 | 203 | 0.030 |
Why?
| | Mice, Mutant Strains | 1 | 2015 | 309 | 0.030 |
Why?
| | Dilatation, Pathologic | 1 | 2014 | 60 | 0.030 |
Why?
| | Gated Blood-Pool Imaging | 1 | 1994 | 4 | 0.030 |
Why?
| | Health | 1 | 2014 | 84 | 0.030 |
Why?
| | Heterozygote | 1 | 2015 | 305 | 0.030 |
Why?
| | Point Mutation | 1 | 2015 | 239 | 0.030 |
Why?
| | Reproducibility of Results | 2 | 2003 | 3317 | 0.030 |
Why?
| | Activating Transcription Factor 6 | 1 | 2013 | 20 | 0.030 |
Why?
| | Educational Measurement | 1 | 2016 | 295 | 0.030 |
Why?
| | eIF-2 Kinase | 1 | 2013 | 32 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2017 | 530 | 0.030 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2016 | 417 | 0.030 |
Why?
| | Disability Evaluation | 1 | 2015 | 298 | 0.030 |
Why?
| | Lipopolysaccharides | 1 | 2017 | 889 | 0.030 |
Why?
| | Reflex, Stretch | 1 | 1993 | 10 | 0.030 |
Why?
| | Denervation | 1 | 1993 | 23 | 0.020 |
Why?
| | Heart-Lung Transplantation | 1 | 1993 | 13 | 0.020 |
Why?
| | Venous Pressure | 1 | 1992 | 6 | 0.020 |
Why?
| | Endoribonucleases | 1 | 2013 | 78 | 0.020 |
Why?
| | Chemoreceptor Cells | 1 | 1993 | 53 | 0.020 |
Why?
| | Microbiota | 1 | 2021 | 760 | 0.020 |
Why?
| | Age of Onset | 1 | 2014 | 519 | 0.020 |
Why?
| | Cell Cycle Proteins | 1 | 2016 | 617 | 0.020 |
Why?
| | Fingers | 1 | 2013 | 105 | 0.020 |
Why?
| | Tissue Distribution | 1 | 1993 | 333 | 0.020 |
Why?
| | Synaptic Transmission | 1 | 1995 | 297 | 0.020 |
Why?
| | Skin Temperature | 1 | 1992 | 30 | 0.020 |
Why?
| | Ovariectomy | 1 | 2012 | 156 | 0.020 |
Why?
| | Cardiography, Impedance | 1 | 1991 | 9 | 0.020 |
Why?
| | Renal Circulation | 1 | 1991 | 67 | 0.020 |
Why?
| | Cell Line | 1 | 2017 | 2876 | 0.020 |
Why?
| | Task Performance and Analysis | 1 | 1992 | 190 | 0.020 |
Why?
| | Endoplasmic Reticulum | 1 | 2013 | 270 | 0.020 |
Why?
| | Inspiratory Capacity | 1 | 1990 | 3 | 0.020 |
Why?
| | Metformin | 1 | 2014 | 334 | 0.020 |
Why?
| | Acupuncture Therapy | 1 | 1990 | 22 | 0.020 |
Why?
| | Precision Medicine | 1 | 2014 | 419 | 0.020 |
Why?
| | Arousal | 1 | 1991 | 156 | 0.020 |
Why?
| | Blood Pressure Monitors | 1 | 1989 | 2 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2011 | 819 | 0.020 |
Why?
| | Lipoproteins | 2 | 1988 | 160 | 0.020 |
Why?
| | Anorexia Nervosa | 1 | 1990 | 90 | 0.020 |
Why?
| | Total Lung Capacity | 1 | 1988 | 32 | 0.020 |
Why?
| | Fever | 1 | 1990 | 306 | 0.020 |
Why?
| | Menstrual Cycle | 1 | 2009 | 134 | 0.020 |
Why?
| | Saponins | 1 | 1988 | 9 | 0.020 |
Why?
| | Postoperative Period | 1 | 1989 | 358 | 0.020 |
Why?
| | Neural Inhibition | 1 | 1989 | 177 | 0.020 |
Why?
| | Digoxin | 1 | 1988 | 27 | 0.020 |
Why?
| | Ultrasonography, Doppler, Duplex | 1 | 2007 | 43 | 0.020 |
Why?
| | Adrenergic Fibers | 1 | 1987 | 5 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2009 | 1094 | 0.020 |
Why?
| | Child | 3 | 1997 | 21907 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2007 | 205 | 0.020 |
Why?
| | Depressive Disorder | 1 | 1990 | 390 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2013 | 1153 | 0.020 |
Why?
| | Forced Expiratory Volume | 1 | 1988 | 482 | 0.020 |
Why?
| | Down-Regulation | 1 | 2009 | 638 | 0.020 |
Why?
| | Pain Management | 1 | 1990 | 382 | 0.020 |
Why?
| | Fatigue | 1 | 1988 | 337 | 0.020 |
Why?
| | Heart Block | 1 | 1986 | 41 | 0.020 |
Why?
| | Environmental Exposure | 1 | 1991 | 568 | 0.020 |
Why?
| | Peptide Fragments | 1 | 1990 | 695 | 0.020 |
Why?
| | Syncope | 1 | 1986 | 55 | 0.020 |
Why?
| | Blood Proteins | 1 | 1988 | 248 | 0.020 |
Why?
| | Feedback | 1 | 2005 | 174 | 0.010 |
Why?
| | Anabolic Agents | 1 | 1984 | 12 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2011 | 1516 | 0.010 |
Why?
| | Hemostatics | 1 | 2005 | 55 | 0.010 |
Why?
| | Dogs | 1 | 2005 | 426 | 0.010 |
Why?
| | Affect | 1 | 2007 | 312 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2011 | 3038 | 0.010 |
Why?
| | Drug Tolerance | 1 | 1984 | 105 | 0.010 |
Why?
| | Arrhythmias, Cardiac | 1 | 1986 | 328 | 0.010 |
Why?
| | C-Peptide | 1 | 1984 | 162 | 0.010 |
Why?
| | Methods | 1 | 1983 | 67 | 0.010 |
Why?
| | Work Capacity Evaluation | 1 | 2002 | 11 | 0.010 |
Why?
| | Androgens | 1 | 1984 | 186 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1983 | 176 | 0.010 |
Why?
| | Wrestling | 1 | 1982 | 3 | 0.010 |
Why?
| | Heart Arrest | 1 | 1986 | 365 | 0.010 |
Why?
| | Gymnastics | 1 | 1982 | 22 | 0.010 |
Why?
| | Motivation | 1 | 2007 | 589 | 0.010 |
Why?
| | Nutritional Physiological Phenomena | 1 | 2001 | 54 | 0.010 |
Why?
| | Sodium Chloride | 1 | 2001 | 138 | 0.010 |
Why?
| | Efferent Pathways | 2 | 1992 | 19 | 0.010 |
Why?
| | Renal Veins | 1 | 1999 | 18 | 0.010 |
Why?
| | Jugular Veins | 1 | 1999 | 42 | 0.010 |
Why?
| | Models, Cardiovascular | 1 | 2000 | 197 | 0.010 |
Why?
| | Adrenal Cortex Hormones | 1 | 2001 | 496 | 0.010 |
Why?
| | Metabolic Clearance Rate | 1 | 1998 | 116 | 0.010 |
Why?
| | Oscillometry | 1 | 1998 | 36 | 0.010 |
Why?
| | Self Concept | 1 | 1996 | 256 | 0.010 |
Why?
| | Injections, Intraventricular | 1 | 1990 | 55 | 0.010 |
Why?
| | Pain Measurement | 1 | 1992 | 548 | 0.000 |
Why?
| | Pancreatic Hormones | 1 | 1988 | 3 | 0.000 |
Why?
| | Cardenolides | 1 | 1988 | 1 | 0.000 |
Why?
| | Glycerol | 1 | 1988 | 91 | 0.000 |
Why?
| | Growth Hormone | 1 | 1988 | 102 | 0.000 |
Why?
| | Thyroid Hormones | 1 | 1988 | 60 | 0.000 |
Why?
| | Fatty Acids, Nonesterified | 1 | 1988 | 158 | 0.000 |
Why?
| | Insulin-Like Growth Factor I | 1 | 1988 | 324 | 0.000 |
Why?
| | Differential Threshold | 1 | 1985 | 5 | 0.000 |
Why?
| | Maximal Voluntary Ventilation | 1 | 1985 | 9 | 0.000 |
Why?
| | Risk | 1 | 1987 | 913 | 0.000 |
Why?
| | Bicycling | 1 | 1985 | 113 | 0.000 |
Why?
| | Ammonia | 1 | 1984 | 62 | 0.000 |
Why?
| | Action Potentials | 1 | 1987 | 486 | 0.000 |
Why?
| | Testosterone | 1 | 1984 | 402 | 0.000 |
Why?
| | Substance-Related Disorders | 1 | 1984 | 1083 | 0.000 |
Why?
|
|
Seals's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|